Roivant Sciences (ROIV) Exchange Rate Effect (2023 - 2026)
Roivant Sciences' (ROIV) quarterly Exchange Rate Effect came in at $315000.0 in Q2 2026, down 61.35% on a YoY basis from $815000.0 in Q2 2025, and down 87.15% quarter-over-quarter from $2.5 million in Q4 2025.
Analysis
Roivant Sciences (ROIV) Exchange Rate Effect (2023 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has reported Exchange Rate Effect for 4 consecutive years, with $315000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Exchange Rate Effect fell 61.35% year-over-year to $315000.0; the trailing twelve-month figure through Jun 2026 stood at $4.8 million (up 9.94% YoY), and the FY2026 full-year result was $3.8 million, up 404.28% from the prior year.
- Exchange Rate Effect declined to $315000.0 in Q2 2026 per ROIV's latest filing, from $2.5 million in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $5.0 million in Q3 2024 and bottomed at -$2.7 million in Q2 2024.
- Historically, Exchange Rate Effect has averaged $822600.0 across 4 years, with a median of $1.0 million in 2025.
- The widest YoY moves for Exchange Rate Effect: up 446.84% in 2024, down 2241.88% in 2024.
- Over 4 years, Exchange Rate Effect stood at $1.5 million in 2023, then dropped by 15.98% to $1.2 million in 2024, then surged by 98.3% to $2.5 million in 2025, then tumbled by 87.15% to $315000.0 in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered $315000.0, $2.5 million, and $1.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.21 Bn | 197.22 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.48 Bn | 178.31 Bn | 6.22 Bn | -19.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.46 Bn | 2.84 Bn | -3.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.80 Bn | 74.80 Bn | 3.93 Bn | -300,000.00 |
| 5 | Argenx Se | 61.62 Bn | 56.43 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.72 Bn | 49.58 Bn | 52.00 Mn | -2.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.15 Bn | 30.84 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Biogen | 31.30 Bn | 30.02 Bn | 1.96 Bn | -3.40 Mn |
| 9 | Roivant Sciences | 30.28 Bn | 30.28 Bn | 1.16 Mn | 315,000.00 |
| 10 | Insmed | 28.21 Bn | 27.05 Bn | 358.27 Mn | -287,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 315,000.00 |
| Dec 31, 2025 | 2.45 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | 815,000.00 |
| Dec 31, 2024 | 1.24 Mn |
| Sep 30, 2024 | 5.04 Mn |
| Jun 30, 2024 | -2.74 Mn |
| Dec 31, 2023 | 1.47 Mn |
| Sep 30, 2023 | -1.45 Mn |
| Jun 30, 2023 | -117,000.00 |